Combined Treatment with an LHRH Agonist and the Antiandrogen Flutamide in Prostate Cancer
| Autor: | G. Monfette, Yves Lacourcière, Emond J, M. Giguere, Fernand Labrie, R. St. Arnaud, A. Bélanger, André Dupont |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.drug_class Antiandrogen medicine.disease Flutamide chemistry.chemical_compound Prostate cancer Endocrinology medicine.anatomical_structure chemistry Prostatic acid phosphatase Prostate Internal medicine Dihydrotestosterone Medicine Orchiectomy business Luteinizing hormone medicine.drug |
| Zdroj: | Neural and Endocrine Peptides and Receptors ISBN: 9781468451542 |
| DOI: | 10.1007/978-1-4684-5152-8_44 |
| Popis: | The original observation that treatment of adult male rats with LHRH agonists causes a marked inhibition of testosterone secretion accompanied by a loss in secondary sex organ weight (Labrie et ai, 1978, 1980) opened a new era in the treatment of androgen-dependent diseases. When administered to adult men in appropriate doses by the subcutaneous route, these peptides decrease serum testosterone and dihydrotestosterone to castrated levels (Labrie et al., 1980; Faure et ai, 1982; Jacobi and Wenderoth, 1982). Since LHRH agonists have no adverse side effects other than those related to low circulating levels of androgens, they offer an advantageous alternative to orchiectomy and treatment with estrogens in advanced carcinoma of the prostate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|